Based on these preclinical studies, various clinical trials are evaluating whether the anti-MM activity of CD38 antibodies can be enhanced by immuno-oncology combinations with PD-1 or PD-L1 inhibitors (5). This evidence concerns the gene CD38 and Miyoshi myopathy.